SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that the company will participate in three upcoming investor
conferences.
2018 Cantor Global Healthcare Conference
Management will present a corporate overview at the 2018 Cantor
Global Healthcare Conference, which is being held in New York on October
1-3, 2018.
Details of the presentation are as follows:
|
Time/Date:
|
Monday, October
1 at 1:45 - 2:15 PM ET (webcast available)
|
|
Location:
|
Intercontinental
Barclay Hotel, New York
|
|
Room:
|
Empire Ballroom
1
|
The company will also participate in 1-on-1 meetings at the
Cantor conference.
2018 BIO Investor Forum
The company will attend and participate in 1-on-1 meetings at
the 2018 BIO Investor Forum. The conference is being held in
San Francisco on October 17-18, 2018, at the Westin St.
Francis.
BTIG Biotechnology Conference
The company will attend and participate in the BTIG
Biotechnology Conference, which is being held in New York on October 25,
2018, at the Langham Hotel.
To access the live webcast of the Cantor presentation, please
visit "Webcasts & Presentations" within the News & Events
section of Viking's Investors page at www.vikingtherapeutics.com.
Additionally, a replay of the webcast will be available on the
Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development of novel, first-in-class or best-in-class therapies for
metabolic and endocrine disorders. The company's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
small molecule thyroid beta agonist. In a Phase 2 trial for
the treatment of non-alcoholic fatty liver disease and elevated
LDL-C, patients who received VK2809 demonstrated statistically
significant reductions in LDL-C and liver fat content. VK2809 was
shown to be safe and well-tolerated in the study. The
company's second clinical program is VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared to patients who received
placebo. The company is also developing VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for type 2 diabetes. Additional programs include
novel and selective agonists of the thyroid beta receptor for GSD
Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia. Viking
holds exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, including those
noted above, which are based on small molecules licensed from
Ligand Pharmaceuticals Incorporated.
View original
content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-300718909.html
SOURCE Viking Therapeutics, Inc.